A nitroblue tetrazolium (NBT) test showed positive reactions in all of 22 patients with Hodgkin disease and in nine of 12 patients with malignant lymphoma. No correlation was noted in the degree of NBT reduction, activity of the diseases, presence of fever, leukocytosis, stage of the diseases, or treatment modality. Patients with Hodgkin disease and malignant lymphoma may retain an enhanced phagocytic and bactericidal activity in response to unknown stimuli.
Chang JC, Appleby J, Bennett JM. Nitroblue Tetrazolium Test in Hodgkin Disease and Other Malignant Lymphomas. Arch Intern Med. 1974;133(3):401–403. doi:10.1001/archinte.1974.00320150075008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: